United States - English - NLM (National Library of Medicine)

bayer healthcare pharmaceuticals inc. - levonorgestrel (unii: 5w7sia7yzw) (levonorgestrel - unii:5w7sia7yzw) - levonorgestrel 52 mg - mirena is indicated for prevention of pregnancy for up to 8 years; replace after the end of the eighth year. mirena is indicated for the treatment of heavy menstrual bleeding for up to 5 years in women who choose to use intrauterine contraception as their method of contraception; replace after the end of the fifth year if continued treatment of heavy menstrual bleeding is needed. the use of mirena is contraindicated when one or more of the following conditions exist: the use of mirena is contraindicated in pregnancy or with a suspected pregnancy and mirena may cause adverse pregnancy outcomes [see contraindications (4 ), warnings and precautions (5.1 , 5.2 )]. if a woman becomes pregnant with mirena in place, the likelihood of ectopic pregnancy is increased and there is an increased risk of miscarriage, sepsis, premature labor, and premature delivery. remove mirena, if possible, if pregnancy occurs in a woman using mirena. if mirena cannot be removed, follow the pregnancy closely [see warnings and precautio

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - levonorgestrel, quantity: 52 mg - drug delivery system, intrauterine - excipient ingredients: dimethylsiloxane/methylvinylsiloxane cross linked elastomer - contraception. treatment of idiopathic menorrhagia. prevention of endometrial hyperplasia during oestrogen replacement therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - levonorgestrel 52mg - intrauterine contraceptive device - 52 mg - active: levonorgestrel 52mg - contraception

Israel - English - Ministry of Health

bayer israel ltd - levonorgestrel - intrauterine device - levonorgestrel 52 mg - levonorgestrel and estrogen - levonorgestrel and estrogen - contraception and idiopathic menorrhagia. protection from endometrial hyperplasia during estrogen replacement therapy.